First-line immunotherapy: Hype rather than near reality in gastric cancer

Affiliations

¹ Department of Medical Oncology, Homi Bhabha National Institute, Tata Memorial Centre Parel, Mumbai, Maharashtra, India.
² Department of GI and HPB Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Centre Parel, Mumbai, Maharashtra, India.

Comment

Prabhat Bhargava et al. Natl Med J India. 2022 Mar-Apr.

. 2022 Mar-Apr;35(2):98-99.

doi: 10.25259/NMJI_645_21.

¹ Department of Medical Oncology, Homi Bhabha National Institute, Tata Memorial Centre Parel, Mumbai, Maharashtra, India.
² Department of GI and HPB Surgical Oncology, Homi Bhabha National Institute, Tata Memorial Centre Parel, Mumbai, Maharashtra, India.

No abstract available

Comment on

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. Janjigian YY, et al. Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. Lancet. 2021. PMID: 34102137 Free PMC article. Clinical Trial.

1. Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, et al. A real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med. 2021; 10:1525-34
1. Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020; 6:1571-80
1. Boku NR, Ryu MH, Oh D, Oh SC, Chung HC, Lee K, et al. LBA7_PR-Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/ GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann Oncol. 2020; 31: (Suppl 4)S1142-215
1. Hagi T, Kurokawa Y, Kawabata R, Omori T, Matsuyama J, Fujitani K, et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. 2020; 123:965-72
1. Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJ, Schramel FM, Klungel OH, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep. 2021; 11:6306